Clinical Trial Update: Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures [Phase 3]

View source ↗

Summary

Open-label extension study of Rufinamide as adjunctive therapy in patients with refractory partial seizures; terminated with posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Onset Seizures

Drugs mentioned

• Rufinamide (Rufinamide)

Snippet

Sponsor: Eisai Inc. | Conditions: Refractory Partial Onset Seizures | Phase 3 | Status: TERMINATED | Results posted: 2012-12-10